Topics

AstraZeneca's Imfinzi, tremelimumab regimens delay disease progression in lung cancer study http://www.firstwordpharma.com/node/1676841  $AZN

12:03 EDT 28 Oct 2019 | FirstWord Pharma

AstraZeneca's Imfinzi, tremelimumab regimens delay disease progression in lung cancer study http://www.firstwordpharma.com/node/1676841 

Original Article: AstraZeneca's Imfinzi, tremelimumab regimens delay disease progression in lung cancer study http://www.firstwordpharma.com/node/1676841  $AZN

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Imfinzi, tremelimumab regimens delay disease progression in lung cancer study http://www.firstwordpharma.com/node/1676841  $AZN"

Quick Search

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...